Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zealand, Protagonist to develop peptide drug
As part of the collaboration Protagonist will provide a valid and proprietary technology platform for the discovery and optimisation of novel DRPs (disulfide rich peptides). Zealand Pharma will
As part of the collaboration Protagonist will provide a valid and proprietary technology platform for the discovery and optimisation of novel DRPs (disulfide rich peptides). Zealand Pharma will
The proposed filling line is expected produce up to 1 million units per day and is well suited for the aseptic filling of high-volume products, like vaccines. The
The collaboration will focus on improving patient health outcomes through new solutions that aid shared decision making between patients and physicians. Geisinger Health System president and chief executive
The five year, $17.9m contract will support the advanced development of candidate vaccine components and technologies that accelerate the immune response for use in post-event settings following the
The center will support development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures, ensure domestic pandemic influenza vaccine manufacturing surge capacity, share facility construction costs, and provide
As per the agreement, Merck receives worldwide rights to develop and commercialize biotherapeutic drug conjugates aimed at a number of pre-specified targets while Ambrx will earn $15m upfront
The new system, which is available in single-, twin-, triplet-, and quad-vessel configurations, is flexible to handle volumes from 4l to 10l. The XDR-10 is an integral component
Sanofi Pasteur already kept approximately 1,000 vials of the vaccine out of circulation and another 4,700 vials on the market are being immediately recalled. BCG is used to
The clean room, within its Houston, Texas operations, supports viral-based GMP manufacturing projects of up to 2,000l working volumes. Lonza viral-based therapeutics head David Enloe said the clients’
Based on the data from interim analysis the company decided to discontinue the double-blind, placebo-controlled study. The randomized study was designed to evaluate the efficacy and safety of